[1]WANG QR, ZHANG Y, MU D, et al.Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography[J].J Clin Hepatol, 2017, 33 (5) :896-898. (in Chinese) 王群茹, 张勇, 牟东, 等.治疗性经内镜逆行胰胆管造影术后胆道出血与原发疾病的关系[J].临床肝胆病杂志, 2017, 33 (5) :896-898.
|
[2]XIANG S, WAN YL, CHEN X.Hilar cholangiocarcinoma:Controversies on the extent of surgical resection aiming at cure[J].Int J Colorectal Dis, 2015, 30 (2) :159-171.
|
[3]HU HJ, HUI M, TAN YQ, et al.Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma[J].Springerplus, 2016, 5 (1) :551-559.
|
[4]LI M, KAI L, QI X, et al.Percutaneous transhepatic biliary stent implantation for obstructive jaundice of perihilar cholangiocarcinoma:a prospective study on predictors of stent patency and survival in 92 patients[J].J Vasc Interv Radiol, 2016, 27 (7) :1047-1055.
|
[5]CUI DP, ZHANG YC, GAO SQ, et al.Value of serum carbohydrate antigens 19-9 and 24-2 in diagnosis of benign and malignant biliary tract diseases[J].J Clin Hepatol, 2016, 32 (7) :1364-1367. (in Chinese) 崔大鹏, 张迎春, 高树全, 等.血清糖链抗原19-9、糖链抗原24-2对良恶性胆道疾病的诊断价值[J].临床肝胆病杂志, 2016, 32 (7) :1364-1367.
|
[6]FENG F, TIAN Y, XU G, et al.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer[J].BMC Cancer, 2017, 17 (1) :737-743.
|
[7] Anti-cancer Association of China.Guideline for the diagnosis and therapy of hilar cholangiocarcinoma (2015) [J].Chin J Hepatobiliary Surg, 2015, 21 (8) :505-511. (in Chinese) 中国抗癌协会.肝门部胆管癌规范化诊治专家共识 (2015) [J].中华肝胆外科杂志, 2015, 21 (8) :505-511.
|
[8]EBATA T, KOSUGE T, HIRANO S, et al.Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas[J].Br J Surg, 2014, 101 (2) :79-88.
|
[9]WANG Y, YANG H, SHEN C, et al.Surgical procedure and long-term survival of hilar cholangiocarcinoma[J].Int J Clin Exp Med, 2015, 8 (1) :1122-1128.
|
[10]CAI WK, LIN JJ, HE GH, et al.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma[J].Int J Clin Exp Pathol, 2014, 7 (11) :7890-7898.
|
[11]YIN XY, LIU X, CHEN W, et al.Long-term outcomes and prognostic factors of surgical resection of hilar cholangiocarcinoma[J].Chin J Dig Surg, 2016, 15 (4) :329-333. (in Chinese) 殷晓煜, 刘鑫, 陈伟, 等.肝门部胆管癌手术切除的远期疗效及预后因素分析[J].中华消化外科杂志, 2016, 15 (4) :329-333.
|
[12]SUI XL, TANG HH, XIAO GF, et al.Clinical efficacy and prognostic factors analysis of hilar cholangiocarcinoma in 322 patients[J].Chin J Dig Surg, 2017, 16 (4) :391-397. (in Chinese) 隋鑫磊, 汤恢焕, 肖广发, 等.322例肝门部胆管癌的临床疗效及预后因素分析[J].中华消化外科杂志, 2017, 16 (4) :391-397.
|
[13]LI L, WANG J, SHANG PZ.Expressions of Annexin A1 and CA19-9 in cholangiocarcinoma and their clinicopathological significance[J].China J Modern Med, 2016, 26 (10) :31-35. (in Chinese) 李辽, 王金, 尚培中.膜联蛋白A1和CA19-9在胆管癌中的表达及其临床意义[J].中国现代医学杂志, 2016, 26 (10) :31-35.
|
[14]HU SZ, WANG X, KONG J.Clinical data and differential diagnosis of hilar cholangiocarcinoma and hilar benign diseases[J].Chin J Bases and Clin Gen Surg, 2017, 1 (3) :343-348. (in Chinese) 胡尚志, 王鑫, 孔静.肝门胆管癌与肝门部良性疾病的临床资料比较和鉴别诊断[J].中国普外基础与临床杂志, 2017, 1 (3) :343-348.
|
[15]WANG JK, HU HJ, SHRESTHA A, et al.Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?[J].Oncotarget, 2017, 8 (28) :45335-45344.
|
[16]LAI JF, XU WN, NOH SH, et al.Effect of World Health Organization (WHO) histological classification on predicting lymph node metastasis and recurrence in early gastric cancer[J].Med Sci Monit, 2016, 22 (5) :3147-3153.
|
[17]DEOLIVEIRA ML, CUNNINGHAM SC, CAMERON JL, et al.Cholangiocarcinoma:thirty-one-year experience with 564 patients at a single institution[J].Ann Surg, 2007, 245 (5) :755-762.
|